Colorectal Cancer
Conditions
Keywords
Metastatic Colorectal Cancer, Cancer
Brief summary
This Phase II, multicenter, double-blind, randomized, active-controlled trial is designed to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) when administered at a dose of 5 mg/kg every 2 weeks in combination with 5 FU (fluorouracil)/leucovorin versus 5 FU/leucovorin alone in subjects with previously untreated metastatic colorectal cancer who are not optimal candidates to receive first-line CPT-11 (irinotecan). A total of 48 doses of rhuMAb VEGF may be administered during this study (maximum of 96 weeks of therapy).
Interventions
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Age \>=18 years * Use of an effective means of contraception in women of childbearing potential * Histologically confirmed (resected or biopsied primary tumor) colorectal carcinoma with evidence of metastases (i.e., by radiographic imaging or biopsy) * Ability to tolerate CT contrast dye. * Bi-dimensionally measurable disease (minimum of two lesions) * Life expectancy of \>3 months * Willingness and capability to be accessible for follow-up until death * In addition, subjects must meet at least one of the following criteria to be eligible for study entry: \*Age \>=65 years; \*ECOG performance status of 1 or 2; \*Albumin \<=3.5 g/dL; \*Prior radiotherapy to the abdomen or pelvis; and, \*in the opinion of the treating physician, not be an optimal candidate for first-line CPT-11
Exclusion criteria
* Prior administration of chemotherapy other than adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole * Administration of adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole completed \<=12 months prior to Day 0 * Administration of fluoropyrimidines as a radiosensitizer during pelvic radiotherapy for rectal cancer completed \<=12 months prior to Day 0 * Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response * Radiotherapy within 14 days prior to Day 0 * Prior administration of biotherapy for colorectal cancer * Evidence of clinically detectable ascites prior to Day 0 * Other invasive malignancies within 5 years of Day 0 (other than basal cell carcinoma of the skin) * History or evidence upon physical examination of CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, or any brain metastases) * Serious, nonhealing wound, ulcer, or bone fracture * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure within 28 days prior to Day 0, or open biopsy, significant traumatic injury, or anticipation of need for major surgical procedure during the course of the study; fine needle aspirations within 7 days prior to Day 0 * Current or recent (within the 10 days prior to Day 0) use of oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanent indwelling IV catheters) or thrombolytic agent * Chronic, daily treatment with aspirin (\>325 mg/day) or nonsteroidal anti-inflammatory medications (of the kind known to inhibit platelet function) * Pregnancy (positive pregnancy test) or lactation * Proteinuria at baseline or clinically significant impairment of renal function * Current or recent (within 28 days prior to Day 0) participation in another experimental drug study * Active infection requiring parenteral antibiotics on Day 0 * Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix H), serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year prior to Day 0 * ECOG performance status of \>2 * Screening clinical laboratory values: \*ANC of \<=1500/uL; \*Platelet count of \<=75,000/uL; \*International normalized ratio (INR) of \>=1.5; \*Total bilirubin of \>2.0 mg/dL; \*AST or ALT of \>=5 times the upper limit of normal for subjects with documented liver metastases; \>2.5 times the upper limit of normal for subjects without evidence of liver metastases; \*Serum creatinine of \>2.0 mg/dL; \*Hemoglobin of \<9 gm/dL (may be transfused to maintain or exceed this level); \*Proteinuria (24-hour urine collection demonstrated \>=500 mg of protein/24 hr) * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications * Inability to comply with the study visit and follow-up schedule or procedures
Outcome results
None listed